⌘K
Loading ticker…
Aclaris Therapeutics, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Aclaris Therapeutics, Inc. (ACRS) has a 3-month relative strength percentile of 87 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 81. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.3%, relative volume 5.98×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 87, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ACRS is in a stage 2 uptrend, week 2. Currently in a 30-day base; basing ADR 5.6% (broad 6.5%). VCP detected: inconclusive. RS line at new high since base start. Distance from 50d / 200d: 10.4% / 51.0%.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
ACRS is held by 4 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $15M notional. Top 3 carry $28M.
Top 4 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $15M |
| IWMiShares Russell 2000 ETF | 0.01% | $9M |
| VXFVanguard Extended Market ETF | 0.01% | $4M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $1M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ACRS Jan avg: 8.60% median: 8.89% win: 100% σ: 6.91% n: 4 2022-04-12 → 2026-05-29 | ACRS Feb avg: -15.42% median: -19.00% win: 25% σ: 12.50% n: 4 2022-04-12 → 2026-05-29 | ACRS Mar avg: -5.83% median: -9.46% win: 50% σ: 29.36% n: 4 2022-04-12 → 2026-05-29 | ACRS Apr avg: -1.82% median: -2.42% win: 40% σ: 15.31% n: 5 2022-04-12 → 2026-05-29 | ACRS May avg: -1.30% median: 3.82% win: 60% σ: 8.96% n: 5 2022-04-12 → 2026-05-29 | ACRS Jun avg: 9.35% median: 7.97% win: 75% σ: 11.15% n: 4 2022-04-12 → 2026-05-29 (current) | ACRS Jul avg: 8.78% median: 9.07% win: 75% σ: 10.93% n: 4 2022-04-12 → 2026-05-29 | ACRS Aug avg: -1.69% median: -4.35% win: 50% σ: 21.69% n: 4 2022-04-12 → 2026-05-29 | ACRS Sep avg: -3.40% median: -2.05% win: 0% σ: 3.41% n: 4 2022-04-12 → 2026-05-29 | ACRS Oct avg: 15.47% median: 15.90% win: 50% σ: 37.18% n: 4 2022-04-12 → 2026-05-29 | ACRS Nov avg: 13.06% median: 4.90% win: 50% σ: 85.37% n: 4 2022-04-12 → 2026-05-29 | ACRS Dec avg: -2.30% median: 4.92% win: 75% σ: 25.56% n: 4 2022-04-12 → 2026-05-29 |